申请人:Max-Planck-Gesellschaft zur Förderung der
Wissenschaften e.V.
公开号:EP2698367A1
公开(公告)日:2014-02-19
The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.
本发明涉及新型取代苯并咪唑和立体异构体形式,以及这些化合物的前药、溶剂化合物、水合物和/或药学上可接受的盐,以及含有至少一种这些取代苯并咪唑的药物组合物,与药学上可接受的载体、赋形剂和/或稀释剂一起。已确定这些新型取代苯并咪唑结合到PDEδ的藤黄素结合口袋,通过抑制PDEδ与K-Ras的结合以及通过改变其定位导致细胞死亡或抑制增殖,从而对癌症的预防和治疗有用。